Valneva SE (0OB3.L)
EUR 1.82
(2.0%)
EUR 1.82
(2.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 82.73 Million EUR | 160.37% |
| 2022 | -137.04 Million EUR | 40.92% |
| 2021 | -231.98 Million EUR | -134.47% |
| 2020 | -98.94 Million EUR | -576.21% |
| 2019 | 20.77 Million EUR | 206.63% |
| 2018 | -19.48 Million EUR | -151.34% |
| 2017 | 37.95 Million EUR | -19.66% |
| 2016 | 47.23 Million EUR | -21.73% |
| 2015 | 60.34 Million EUR | 36.23% |
| 2014 | 44.29 Million EUR | 27.39% |
| 2013 | 34.77 Million EUR | 491.18% |
| 2012 | 5.88 Million EUR | 289.07% |
| 2011 | -3.11 Million EUR | 88.87% |
| 2010 | -27.95 Million EUR | -62.71% |
| 2009 | -17.17 Million EUR | -21.96% |
| 2008 | -14.08 Million EUR | -45.1% |
| 2007 | -9.7 Million EUR | -401.18% |
| 2006 | 3.22 Million EUR | 126.81% |
| 2005 | 1.42 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 35.03 Million EUR | -57.66% |
| 2024 Q2 | 78.22 Million EUR | 123.29% |
| 2023 Q2 | -55.17 Million EUR | 45.77% |
| 2023 Q3 | 23.25 Million EUR | 142.14% |
| 2023 FY | 82.73 Million EUR | 160.37% |
| 2023 Q1 | -101.75 Million EUR | 25.75% |
| 2023 Q4 | 82.73 Million EUR | 255.85% |
| 2022 Q3 | -99.42 Million EUR | 50.94% |
| 2022 FY | -137.04 Million EUR | 40.92% |
| 2022 Q1 | -195.74 Million EUR | 15.62% |
| 2022 Q2 | -202.65 Million EUR | -3.53% |
| 2022 Q4 | -137.04 Million EUR | -37.84% |
| 2021 Q2 | -218.23 Million EUR | -68.0% |
| 2021 FY | -231.98 Million EUR | -134.47% |
| 2021 Q4 | -231.98 Million EUR | 0.0% |
| 2021 Q1 | -129.9 Million EUR | -31.29% |
| 2020 FY | -98.94 Million EUR | -576.21% |
| 2020 Q1 | 18.45 Million EUR | -11.17% |
| 2020 Q2 | -87.09 Million EUR | -571.9% |
| 2020 Q3 | -44.91 Million EUR | 48.44% |
| 2020 Q4 | -98.94 Million EUR | -120.31% |
| 2019 Q3 | 16.43 Million EUR | 335.57% |
| 2019 FY | 20.77 Million EUR | 206.63% |
| 2019 Q2 | 3.77 Million EUR | -55.3% |
| 2019 Q1 | 8.44 Million EUR | 143.32% |
| 2019 Q4 | 20.77 Million EUR | 26.43% |
| 2018 Q4 | -19.48 Million EUR | -171.36% |
| 2018 Q2 | 27.35 Million EUR | -9.86% |
| 2018 Q1 | 30.34 Million EUR | -20.04% |
| 2018 FY | -19.48 Million EUR | -151.34% |
| 2018 Q3 | 27.3 Million EUR | -0.16% |
| 2017 Q2 | 30.16 Million EUR | 0.1% |
| 2017 Q4 | 37.95 Million EUR | 29.3% |
| 2017 Q3 | 29.35 Million EUR | -2.71% |
| 2017 FY | 37.95 Million EUR | -19.66% |
| 2017 Q1 | 30.13 Million EUR | -36.19% |
| 2016 FY | 47.23 Million EUR | -21.73% |
| 2016 Q2 | 41.81 Million EUR | -14.7% |
| 2016 Q4 | 47.23 Million EUR | 18.35% |
| 2016 Q3 | 39.91 Million EUR | -4.55% |
| 2016 Q1 | 49.01 Million EUR | -18.77% |
| 2015 FY | 60.34 Million EUR | 36.23% |
| 2015 Q1 | 51.86 Million EUR | 17.09% |
| 2015 Q2 | 45.58 Million EUR | -12.12% |
| 2015 Q3 | 50.73 Million EUR | 11.31% |
| 2015 Q4 | 60.34 Million EUR | 18.95% |
| 2014 FY | 44.29 Million EUR | 27.39% |
| 2014 Q1 | 43.61 Million EUR | 25.44% |
| 2014 Q2 | 39.32 Million EUR | -9.83% |
| 2014 Q4 | 44.29 Million EUR | 7.3% |
| 2014 Q3 | 41.28 Million EUR | 4.97% |
| 2013 FY | 34.77 Million EUR | 491.18% |
| 2013 Q4 | 34.77 Million EUR | 4.06% |
| 2013 Q3 | 33.41 Million EUR | -47.63% |
| 2013 Q2 | 63.8 Million EUR | 429.19% |
| 2013 Q1 | 12.05 Million EUR | 104.98% |
| 2012 Q2 | 6.09 Million EUR | 0.0% |
| 2012 Q4 | 5.88 Million EUR | 0.0% |
| 2012 FY | 5.88 Million EUR | 289.07% |
| 2011 FY | -3.11 Million EUR | 88.87% |
| 2011 Q2 | -22.8 Million EUR | 0.0% |
| 2011 Q4 | -3.11 Million EUR | 0.0% |
| 2010 Q2 | -1.21 Million EUR | 0.0% |
| 2010 FY | -27.95 Million EUR | -62.71% |
| 2010 Q4 | -27.95 Million EUR | 0.0% |
| 2009 FY | -17.17 Million EUR | -21.96% |
| 2009 Q4 | -17.17 Million EUR | 0.0% |
| 2008 FY | -14.08 Million EUR | -45.1% |
| 2007 FY | -9.7 Million EUR | -401.18% |
| 2006 FY | 3.22 Million EUR | 126.81% |
| 2005 FY | 1.42 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Boiron SA | -60.34 Million EUR | 237.112% |
| Laboratorios Farmaceuticos Rovi, S.A. | 21.31 Million EUR | -288.195% |
| Vetoquinol SA | -129.83 Million EUR | 163.723% |
| AB Science S.A. | 13.03 Million EUR | -534.722% |
| Nanobiotix S.A. | -29.8 Million EUR | 377.638% |
| PHAXIAM Therapeutics S.A. | -275 Thousand EUR | 30185.818% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 546.642% |
| BioSenic S.A. | 28.04 Million EUR | -195.022% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 142.11% |
| Formycon AG | 2.45 Million EUR | -3275.602% |